Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SK&F Velocity Agreement

Executive Summary

SK&F reached interim agreement with the Velocity Hospital Group during the week of May 21-25 in relation to Northwestern Drug (Wash.) private antitrust suit v. SK&F and four other mfrs. SK&F will provide normal chargeback allowance on products purchased by Velocity Group plus up to 3% of whsle. price to compensate Velocity Group for extra costs of having to search for alternative supplier. If SK&F prevails in the suit, reimbursement for extra costs will be returned by hospitals to the mfr. Velocity group had claimed it would be put out of business by mfrs. refusal to do business with Northwestern.

SK&F reached interim agreement with the Velocity Hospital Group during the week of May 21-25 in relation to Northwestern Drug (Wash.) private antitrust suit v. SK&F and four other mfrs. SK&F will provide normal chargeback allowance on products purchased by Velocity Group plus up to 3% of whsle. price to compensate Velocity Group for extra costs of having to search for alternative supplier. If SK&F prevails in the suit, reimbursement for extra costs will be returned by hospitals to the mfr. Velocity group had claimed it would be put out of business by mfrs. refusal to do business with Northwestern.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS006654

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel